1.710USD-3.94%Mkt Cap: 7.88M USDP/E: —Last update: 2026-05-26
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT pac…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap7.88M USD
Enterprise Value412.59K USD
Revenue (TTM)1.27M USD
Gross Profit185.31K USD
Net Income (TTM)-7.75M USD
Revenue/Share9.796 USD
Last Price1.710 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees32
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.05
EV/Revenue0.32
P/S5.93
P/B0.26
EPS (TTM)-150.06
EPS (Forward)—
52W Range
1.6200% of range309.89
52W High309.89 USD
52W Low1.620 USD
Profitability
Gross Margin31.40%
Oper. Margin-484.68%
EBITDA Margin0.00%
Profit Margin-1313.00%
ROE-98.86%
ROA-60.21%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.93M USD
CapEx (TTM)448.25K USD
FCF Margin-197.64%
FCF Yield-31.89%
Net Debt-7.13M USD
Net Debt/EBITDA0.79
Balance Sheet
Debt/Equity0.34
Current Ratio1.45
Quick Ratio1.38
Book Value/Sh6.509 USD
Cash/Share3.321 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateMar 10, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.54M
Float4.54M
Insiders0.06%
Institutions1.57%
Short Interest
Short Ratio0.0d
Short % Float5.31%
Short % Out.5.31%
Shares Short236.19K
Short (prev mo.)1.64M
Technical
SMA 503.383 (-49.5%)
SMA 20070.16 (-97.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.25M
Avg Vol (10d)744.82K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—